Merck broke ground in April of 2025 on a $1 billion biologics center of excellence in Wilmington, Del. Leveraging sophisticated automation solutions and artificial intelligence technologies, the 470,000-sf facility will offer laboratory, manufacturing, and logistics capabilities. The leading-edge structure will enable the launch and commercial production of next-generation biologics and therapies, including potent antibody-drug conjugates (ADCs).
Furthering the company's commitment to ongoing investment in U.S. infrastructure, Merck Wilmington Biotech will serve as a key domestic center for the supply of the immunotherapy drug Keytruda® (pembrolizumab). The laboratory component is expected to be fully operational by 2028, with production of investigational compounds anticipated to start by 2030.
Jacobs is the engineering contractor for the project, which represents an estimated construction value of $330 million. The development is located on a leased site at the 164-acre Chestnut Run Innovation & Science Park, a dynamic innovation ecosystem created and managed by MRA Group.
| Organization | Project Role |
|---|---|
|
Engineer
|
|
|
MRA Group
|
Developer
|
